Irritable Bowel Syndrome (IBS): A Review

Keywords: Irritable bowel syndrome, Rome criteria, functional gastrointestinal disorder, Abdominal pain, Bloating

Abstract

Nowadays irritable bowel syndrome is one of the most common functional gastrointestinal disorders (FGIDs) with global prevalence. It’s described by a change in the habit of the bowel system. Pathophysiology of IBS is unclear, therefore; IBS becomes a specific subject for many researchers to investigate and discover some biomarkers associated with IBS. Symptoms are a confusion of abdominal pain and bloating which is demonstrated according to Rome criteria. In this mini-review, we conclude that IBS makes additional complications in patients such as reflux gastro esophagus, dysphagia, and factors related to IBS are varied including gender, food, family, and environment. Furthermore, food and lifestyle have a direct role in the pathophysiology of IBS patients. Finding additional signs and symptoms of IBS is essential for diagnosis because IBS is dependent on symptoms. IBS has a significant association with genetic variants. SLC6A4 (solute carrier family 6, member 4) is a serotonin transporter gene that gained the most attention from various researchers, therefore IBS require further investigation and discussion to demonstrate some biomarkers and factors associated with them.

Downloads

Download data is not yet available.

References

[1]. Ishihara, S., Aziz, M., Oshima, N., Mishima, Y., Imaoka, H., Moriyama, I. & Kinoshita, Y. (2009). Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders? Clin. J. Gastroenterol., 2(1): 9–16. https://doi.org/10.1007/s12328-008-0051-y.
[2]. Alharbi, S.H., Alateeq, F.A., Alshammari, K.I. & Ahmed, H.G. (2019). IBS common features among Northern Saudi population according to Rome IV criteria. AIMS Med. Sci., 6(2): 148–157. https://doi.org/10.3934/medsci.2019.2.148.
[3]. Saha, L. (2014). Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J. Gastroenterol., 20(22): 6759–6773. https://doi.org/10.3748/wjg.v20.i22.6759.
[4]. Cheyette, B.N.R. & Cheyette, S.N.R. (2016). Acute exacerbation of irritable bowel syndrome prevented by prn oral triptan. Clin. J. Gastroenterol., 9(6): 375–378. https://doi.org/10.1007/s12328-016-0689-9.
[5]. Horwitz, B.J. & Fisher, R.S. (2001). The Irritable Bowel Syndrome. N. Engl. J. Med., 344(24): 1846–1850. https://doi.org/10.1056/NEJM200106143442407.
[6]. Kanazawa, M. & Fukudo, S. (2014). Relationship Between Infectious Gastroenteritis and Irritable Bowel Syndrome. Clin. J. Gastroenterol., 7(1): 14-18. https://doi.org/10.1007/s12328-013-0444-4.
[7]. Occhipinti, K. & Smith, J.W. (2012). Irritable Bowel Syndrome: A Review and Update. Clin. Colon Rectal Surg., 25(1): 46–52. https://doi.org/10.1055/s-0032-1301759.
[8]. Talley, N.J. (2001). Serotoninergic Neuroenteric Modulators. Lancet, 358(9298): 2061–2068. https://doi.org/10.1016/S0140-6736(01)07103-3.
[9]. Dunlop, S.P., Coleman, N.S., Blackshaw, E., Perkins, A.C., Singh, G., Marsden, C.A. & Spiller, R.C. (2005). Abnormalities of 5-hydroxytryptamine Metabolism in Irritable Bowel Syndrome. Clin. Gastroenterol. Hepatol., 3(4): 349–357. https://doi.org/10.1016/s1542-3565(04)00726-8.
[10]. Coates, M.D., Mahoney, C.R., Linden, D.R., Sampson, J.E., Chen, J., Blaszyk, H., Crowell, M. D., Sharkey, K.A., Gershon, M.D., Mawe, G.M. & Moses, P.L. (2004). Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology, 126(7): 1657–1664. https://doi.org/10.1053/j.gastro.2004.03.013.
[11]. Drossman, D.A., Camilleri, M., Mayer, E.A. & Whitehead, W.E. (2002). AGA technical review on irritable bowel syndrome. Gastroenterology, 123(6): 2108–2131. https://doi.org/10.1053/gast.2002.37095.
[12]. Van Oudenhove, L., Vandenberghe, J., Demyttenaere, K. & Tack, J. (2010). Psychosocial Factors, Psychiatric Illness and Functional Gastrointestinal Disorders: A Historical Perspective. Digestion, 82(4): 201–210. https://doi.org/10.1159/000269822.
[13]. Sperber, A.D., Dumitrascu, D., Fukudo, S., Gerson, C., Ghoshal, U.C., Gwee, K.A., Hungin, A., Kang, J.Y., Minhu, C., Schmulson, M., Bolotin, A., Friger, M., Freud, T. & Whitehead, W. (2017). The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut, 66(6): 1075–1082. https://doi.org/10.1136/gutjnl-2015-311240.
[14]. Lovell, R.M. & Ford, A.C. (2012). Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin. Gastroenterol. Hepatol., 10(7): 712–721.e4. https://doi.org/10.1016/j.cgh.2012.02.029.
[15]. Inadomi, J.M., Fennerty, M.B. & Bjorkman, D. (2003). Systematic Review: The Economic Impact of Irritable Bowel Syndrome. Aliment. Pharmacol. Ther., 18(7): 671–682. https://doi.org/10.1046/j.1365-2036.2003.t01-1-01736.x.
[16]. Peery, A.F., Crockett, S.D., Barritt, A.S., Dellon, E.S., Eluri, S., Gangarosa, L.M., Jensen, E.T., Lund, J.L., Pasricha, S., Runge, T., Schmidt, M., Shaheen, N.J. & Sandler, R.S. (2015). Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology, 149(7): 1731–1741.e3. https://doi.org/10.1053/j.gastro.2015.08.045.
[17]. Buono, J.L., Carson, R.T. & Flores, N.M. (2017). Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual. Life Outcomes, 15(1): 1–8. https://doi.org/10.1186/s12955-017-0611-2.
[18]. Agarwal, N. & Spiegel, B.M.R. (2011). The Effect of Irritable Bowel Syndrome on Health-Related Quality of Life and Health Care Expenditures. Gastroenterol. Clin. North Am., 40(1): 11–19. https://doi.org/10.1016/j.gtc.2010.12.013.
[19]. Ringstrom, G., Sjovall, H., Simrén, M. & Ung, E.J. (2020). The Importance of a Person-Centered Approach in Diagnostic Workups of Patients With Irritable Bowel Syndrome: A Qualitative Study. Gastroenterol. Nurs., 36(6): 443–451. https://doi.org/10.1097/SGA.0000000000000011.
[20]. Manning, A.P., Thompson, W.G., Heaton, K.W. & Morris, A.F. (1978). Towards positive diagnosis of the irritable bowel. Br. Med. J., 2(6138): 653–654. https://doi.org/10.1136/bmj.2.6138.653.
[21]. Thompson, W.G., Dotevall, G., Drossman, D.A., Heaton, K.W. & Kruis, W. (1989). Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol. Int., 2: 92-95.
[22]. Drossman, D.A., Thompson, W.G., Talley, N.J., Funch-Jensen, P., Janssens, J. & Whitehead, W.E. (1990). Identification of subgroups of functional bowel disorders. Gastroenterol. Int., 3: 159-172.
[23]. Drossman, D.A., Li, Z., Andruzzi, E., Temple, R.D., Talley, N.J., Thompson, W.G., Whitehead, W.E., Janssens, J., Funch-Jensen, P. & Corazziari, E. (1993). U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci., 38(9): 1569–1580. https://doi.org/10.1007/BF01303162.
[24]. Drossman, D.A., Richter, J.E., Talley, N.J., Thompson, G.W., Corazziari, E. & Whitehead, W.E. (1994). The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment – A Multinational Consensus. Boston, Little Brown & Co.
[25]. Fass, R., Longstreth, G.F., Pimentel, M., Fullerton, S., Russak, S.M., Chiou, C.F., Reyes, E., Crane, P., Eisen, G., McCarberg, B. & Ofman, J. (2001). Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch. Intern. Med., 161(17): 2081–2088. https://doi.org/10.1001/archinte.161.17.2081.
[26]. Drossman, D.A., Corazziari, E., Talley, N.J., Thompson, W.G. & Whitehead, W.E. (2000). Rome II. The functional gastrointestinal disorders. diagnosis, pathophysiology and treatment: a multinational consensus. McLean, VA: Degnon Associates.
[27]. Rasquin-Weber, A., Hyman, P., Cucchiara, S., Fleisher, D., Hyams, J., Milla, P. & Staiano, A. (1999). Childhood functional gastrointestinal disorders. Gut, 45(Suppl 2): II60–II68. https://doi.org/10.1136/gut.45.2008.ii60.
[28]. Drossman, D.A., Corazziari, E., Delvaux, M., Spiller, R.C., Talley, N.J., Thompson, W.G. & Whitehead, W.E. (2006). Rome III: The Functional Gastrointestinal Disorders. Degnon Associates, McLean.
[29]. Lacy, B.E. & Patel, N.K. (2017). Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med., 6(11): 99. https://doi.org/10.3390/jcm6110099.
[30]. Kosako, M., Akiho, H., Miwa, H., Kanazawa, M., & Fukudo, S. (2018). Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey. Biopsychosoc. Med., 12: 18. https://doi.org/10.1186/s13030-018-0137-9.
[31]. Vahedi, H., Ansari, R., Mir-Nasseri, M. & Jafari, E. (2010). Irritable bowel syndrome: a review article. Middle East J. Dig. Dis., 2(2): 66–77.
[32]. Yarandi, S.-S., Nasseri-Moghaddam, S., Mostajabi, P. & Malekzadeh, R. (2010). Overlapping Gastroesophageal Reflux Disease and Irritable Bowel Syndrome: Increased Dysfunctional Symptoms. World J. Gastroenterol., 16(10): 1232–1238. https://doi.org/10.3748/wjg.v16.i9.1232.
[33]. White, A.M., Stevens, W.H., Upton, A.R., O'Byrne, P.M. & Collins, S.M. (1991). Airway Responsiveness to Inhaled Methacholine in Patients with Irritable Bowel Syndrome. Gastroenterology, 100(1): 68–74. https://doi.org/10.1016/0016-5085(91)90584-8.
[34]. Hudson, J.I., Goldenberg, D.L., Pope, Jr., H.G., Keck, Jr., P.E. & Schlesinger, L. (1992). Comorbidity of Fibromyalgia With Medical and Psychiatric Disorders. Am. J. Med., 92(4): 363–367. https://doi.org/10.1016/0002-9343(92)90265-d.
[35]. Chang, L. & Heitkemper, M.M. (2002). Gender differences in irritable bowel syndrome. Gastroenterology, 123(5): 1686–1701. https://doi.org/10.1053/gast.2002.36603.
[36]. Lee, O.Y., Mayer, E.A., Schmulson, M., Chang, L. & Naliboff, B. (2001). Gender-related differences in IBS symptoms. Am. J. Gastroenterol., 96: 2184–2193. https://doi.org/10.1111/j.1572-0241.2001.03961.x.
[37]. Talley, N.J., Boyce, P. & Jones, M. (1998). Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut, 42(5): 690-695. https://doi.org/10.1136/gut.42.5.690.
[38]. Corney, R.H. & Stanton, R. (1990). Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J. Psychosom. Res., 34: 483–491. https://doi.org/10.1016/0022-3999(90)90022-v.
[39]. Taub, E., Cuevas, J.L., Cook, E.W., Crowell, M. & Whitehead, W.E. (1995). Irritable bowel syndrome defined by factor analysis gender and race comparisons. Dig. Dis. Sci., 40(12): 2647–2655. https://doi.org/10.1007/BF02220455.
[40]. Ali, A., Toner, B.B., Stuckless, N., Gallop, R., Diamant, N.E., Gould, M.I. & Vidins, E.I. (2000). Emotional abuse, self-blame, and self-silencing in women with irritable bowel syndrome. Psychosom. Med., 62(1): 76-82. https://doi.org/10.1097/00006842-200001000-00011.
[41]. Toner, B.B. & Akman, D. (2000). Gender role and irritable bowel syndrome: literature review and hypothesis. Am. J. Gastroenterol., 95(1): 11–16. https://doi.org/10.1016/S0002-9270(99)00757-1.
[42]. Björkman, I., Dellenborg, L., Ringström, G., Simrén, M. & Jakobsson Ung, E. (2014). The gendered impact of Irritable Bowel Syndrome: a qualitative study of patients' experiences. J. Adv. Nurs., 70(6): 1334-1343. https://doi.org/10.1111/jan.12294.
[43]. Kim, Y.S. & Kim, N. (2018). Sex-Gender Differences in Irritable Bowel Syndrome. J. Neurogastroenterol. Motil., 24(4): 544–558. https://doi.org/10.5056/jnm18082.
[44]. Hayes, P.A., Fraher, M.H. & Quigley, E.M.M. (2014). Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol. Hepatol. (N Y), 10(3): 164-174.
[45]. Fukudo, S. (2007). Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J. Gastroenterol., 42 (Suppl 17): 48-51. https://doi.org/10.1007/s00535-006-1942-7.
[46]. Konturek, P.C., Brzozowski, T. & Konturek, S.J. (2011). Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J. Physiol. Pharmacol., 62(6): 591-599.
[47]. Komuro, H., Sato, N., Sasaki, A., Suzuki, N., Kano, M., Tanaka, Y., Yamaguchi-Kabata, Y., Kanazawa, M., Warita, H., Aoki, M. & Fukudo, S. (2016). Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome. PLoS One, 11(1): e0147817. https://doi.org/10.1371/journal.pone.0147817.
[48]. Chey, W.D. (2018). Diet and Irritable Bowel Syndrome. Gastroenterol. Hepatol. (N Y), 14(5): 309–312.
[49]. Cozma-Petruţ, A., Loghin, F., Miere, D. & Dumitraşcu, D.L. (2017). Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients! World J. Gastroenterol., 23(21): 3771. https://doi.org/10.3748/wjg.v23.i21.3771.
[50]. Halmos, E.P., Power, V.A., Shepherd, S.J., Gibson, P.R. & Muir, J.G. (2014). A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology, 146(1): 67–755. https://doi.org/10.1053/j.gastro.2013.09.046.
[51]. de Roest, R.H., Dobbs, B.R., Chapman, B.A., Batman, B., O'Brien, L.A., Leeper, J.A., Hebblethwaite, C.R. & Gearry, R.B. (2013). The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int. J. Clin. Pract., 67(9): 895-903. https://doi.org/10.1111/ijcp.12128.
[52]. Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H. & Simrén, M. (2015). Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as well as Traditional Dietary Advice: A Randomized Controlled Trial. Gastroenterology, 149(6): 1399–14072. https://doi.org/10.1053/j.gastro.2015.07.054.
[53]. Krogsgaard, L.R., Engsbro, A.L., Jones, M.P. & Bytzer, P. (2017). The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. A prospective, population-based cohort study. Neurogastroenterol. Motil., 29(4): e12986. https://doi.org/10.1111/nmo.12986.
[54]. Andrews, E.B., Eaton, S.C., Hollis, K.A., Hopkins, J.S., Ameen, V., Hamm, L.R., Cook, S.F., Tennis, P. & Mangel, A.W. (2005). Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey. Aliment. Pharmacol. Ther., 22(10): 935–942. https://doi.org/10.1111/j.1365-2036.2005.02671.x.
[55]. Farzaneh, N., Ghobaklou, M., Moghimi-Dehkordi, B., Naderi, N. & Fadai, F. (2013). Effects of demographic factors, body mass index, alcohol drinking and smoking habits on irritable bowel syndrome: a case control study. Ann. Med. Health Sci. Res., 3(3): 391–396. https://doi.org/10.4103/2141-9248.117958.
[56]. Mansouri, A., Rarani, M.A., Fallahi, M. & Alvandi, I. (2017). Irritable bowel syndrome is concentrated in people with higher educations in Iran: an inequality analysis. Epidemiol. Health, 39: e2017005. https://doi.org/10.4178/epih.e2017005.
[57]. Talley N.J. (2005). Environmental versus genetic risk factors for irritable bowel syndrome: clinical and therapeutic implications. Rev. Gastroenterol. Disord., 5(2): 82–88.
[58]. Jha, R.K., Zou, Y., Li, J. & Xia, B. (2010). Irritable Bowel Syndrome (IBS) at a Glance. Br. J. Med. Pract., 3(4): a342.
[59]. Thabane, M. & Marshall, J.K. (2009). Post-infectious irritable bowel syndrome. World J. Gastroenterol., 15(29): 3591–3596. https://doi.org/10.3748/wjg.15.3591.
[60]. Talley, N.J. (2006). Genes and environment in irritable bowel syndrome: one step forward. Gut, 55(12): 1694-1696. https://doi.org/10.1136/gut.2006.108837.
[61]. Sansone, R.A. & Sansone, L.A. (2015). IRRITABLE BOWEL SYNDROME: Relationships with Abuse in Childhood. Innov. Clin. Neurosci., 12(5-6): 34-37.
[62]. Saito, Y.A., Petersen, G.M., Larson, J.J., Atkinson, E.J., Fridley, B.L., de Andrade, M., Locke, G.R., 3rd, Zimmerman, J.M., Almazar-Elder, A.E. & Talley, N.J. (2010). Familial aggregation of irritable bowel syndrome: a family case-control study. Am. J. Gastroenterol., 105(4): 833-841. https://doi.org/10.1038/ajg.2010.116.
[63]. Saito, Y.A. (2011). The role of genetics in IBS. Gastroenterol. Clin. North Am., 40(1): 45–67. https://doi.org/10.1016/j.gtc.2010.12.011.
[64]. Waehrens, R., Ohlsson, H., Sundquist, J., Sundquist, K. & Zöller, B. (2015). Risk of irritable bowel syndrome in first-degree, second-degree and third-degree relatives of affected individuals: a nationwide family study in Sweden. Gut, 64(2): 215–221. https://doi.org/10.1136/gutjnl-2013-305705.
[65]. D'Amato, M. (2013). Genes and functional GI disorders: from casual to causal relationship. Neurogastroenterol. Motil., 25(8): 638–649. https://doi.org/10.1111/nmo.12173.
[66]. Henström, M. & D'Amato, M. (2016). Genetics of irritable bowel syndrome. Mol. Cell. Pediatr., 3(1): 7. https://doi.org/10.1186/s40348-016-0038-6.
[67]. Saito, Y.A. & Talley, N.J. (2008). Genetics of Irritable Bowel Syndrome. Am. J. Gastroenterol., 103(8): 2100-2105. https://doi.org/10.1111/j.1572-0241.2008.02048.x.
[68]. Van Kerkhoven, L.A.S., Laheij, R.J.F. & Jansen, J.B.M.J. (2007). Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment. Pharmacol. Ther., 26(7): 979–986. https://doi.org/10.1111/j.1365-2036.2007.03453.x.
[69]. Camilleri, M., Atanasova, E., Carlson, P.J., Ahmad, U., Kim, H.J., Viramontes, B.E., McKinzie, S. & Urrutia, R. (2002). Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology, 123(2): 425-432. https://doi.org/10.1053/gast.2002.34780.
[70]. Li, Y., Nie, Y., Xie, J., Tang, W., Liang, P., Sha, W., Yang, H. & Zhou, Y. (2007). The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig. Dis. Sci., 52(11): 2942-2949. https://doi.org/10.1007/s10620-006-9679-y.
[71]. Oświęcimska, J., Szymlak, A., Roczniak, W., Girczys-Połedniok, K. & Kwiecień, J. (2017). New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv. Med. Sci., 62(1): 17–30. https://doi.org/10.1016/j.advms.2016.11.001.
[72]. Fukudo, S. & Kanazawa, M. (2011). Gene, environment, and brain-gut interactions in irritable bowel syndrome. J. Gastroenterol. Hepatol., 26 Suppl 3: 110-115. https://doi.org/10.1111/j.1440-1746.2011.06631.x.
[73]. Spiller, R. & Garsed, K. (2009). Postinfectious irritable bowel syndrome. Gastroenterology, 136(6): 1979–1988. https://doi.org/10.1053/j.gastro.2009.02.074.
[74]. El-Salhy, M. (2012). Irritable bowel syndrome: Diagnosis and pathogenesis. World J. Gastroenterol., 18(37): 5151-5163. https://doi.org/10.3748/wjg.v18.i37.5151.
[75]. Chey, W.D., Maneerattaporn, M. & Saad, R. (2011). Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver, 5(3): 253-266. https://doi.org/10.5009/gnl.2011.5.3.253.
[76]. Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N. & Whorwell, P. (2007). Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut, 56(12): 1770–1798. https://doi.org/10.1136/gut.2007.119446.
[77]. Mearin, F., Balboa, A., Badía, X., Baró, E., Caldwell, E., Cucala, M., Díaz-Rubio, M., Fueyo, A., Ponce, J., Roset, M. & Talley, N.J. (2003). Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur. J. Gastroenterol. Hepatol., 15(2): 165-172. https://doi.org/10.1097/00042737-200302000-00010.
[78]. Drossman, D.A., Morris, C.B., Hu, Y., Toner, B.B., Diamant, N., Leserman, J., Shetzline, M., Dalton, C. & Bangdiwala, S.I. (2005). A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology, 128(3): 580–589. https://doi.org/10.1053/j.gastro.2004.12.006.
[79]. Pimentel, M., Hwang, L., Melmed, G.Y., Low, K., Vasiliauskas, E., Ippoliti, A., Yang, J., Lezcano, S., Conklin, J.L. & Sahakian, A. (2010). New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig. Dis. Sci., 55(1): 145-149. https://doi.org/10.1007/s10620-008-0694-z.
[80]. Thompson, W.G., Longstreth, G.F., Drossman, D.A., Heaton, K.W., Irvine, E.J. & Müller-Lissner, S.A. (1999). Functional bowel disorders and functional abdominal pain. Gut, 45 (Suppl 2): II43-II47. https://doi.org/10.1136/gut.45.2008.ii43.
[81]. Böhn, L., Störsrud, S., Törnblom, H., Bengtsson, U. & Simrén, M. (2013). Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am. J. Gastroenterol., 108(5): 634–641. https://doi.org/10.1038/ajg.2013.105.
[82]. Ford, A.C., Marwaha, A., Lim, A. & Moayyedi, P. (2010). Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin. Gastroenterol. Hepatol., 8(5): 401–409. https://doi.org/10.1016/j.cgh.2009.07.020.
[83]. Whitehead, W.E., Palsson, O.S., Levy, R.R., Feld, A.D., Turner, M. & Von Korff, M. (2007). Comorbidity in irritable bowel syndrome. Am. J. Gastroenterol., 102(12): 2767–2776. https://doi.org/10.1111/j.1572-0241.2007.01540.x.
[84]. Enck, P., Aziz, Q., Barbara, G., Farmer, A.D., Fukudo, S., Mayer, E.A., Niesler, B., Quigley, E. M., Rajilić-Stojanović, M., Schemann, M., Schwille-Kiuntke, J., Simren, M., Zipfel, S. & Spiller, R.C. (2016). Irritable bowel syndrome. Nat. Rev. Dis. Primers, 2: 16014. https://doi.org/10.1038/nrdp.2016.14.
[85]. Kruis, W., Thieme, C., Weinzierl, M., Schüssler, P., Holl, J. & Paulus, W. (1984). A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology, 87(1): 1–7.
[86]. Brandt, L.J., Chey, W.D., Foxx-Orenstein, A.E., Quigley, E.M.M., Schiller, L.R., Schoenfeld, P.S., Spiegel, B.M., Talley, N.J. & Moayyedi, P. (2008). An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol., 104(SUPPL. 1): S1-S35. https://doi.org/10.1038/ajg.2008.122.
[87]. Cash, B.D., Rubenstein, J.H., Young, P.E., Gentry, A., Nojkov, B., Lee, D., Andrews, A.H., Dobhan, R. & Chey, W.D. (2011). The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology, 141(4): 1187–1193. https://doi.org/10.1053/j.gastro.2011.06.084.
[88]. Menees, S.B., Powell, C., Kurlander, J., Goel, A., & Chey, W.D. (2015). A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol., 110(3): 444–454. https://doi.org/10.1038/ajg.2015.6.
[89]. Dickinson, B. & Surawicz, C.M. (2014). Infectious Diarrhea: An Overview. Curr. Gastroenterol. Rep., 16(8): 399–6. https://doi.org/10.1007/s11894-014-0399-8.
[90]. Drossman, D.A. & Thompson, W.G. (1992). The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann. Intern. Med., 116(12 Pt 1): 1009–1016. https://doi.org/10.7326/0003-4819-116-12-1009.
[91]. Drossman, D.A. (1995). Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann. Intern. Med., 123(9): 688–697. https://doi.org/10.7326/0003-4819-123-9-199511010-00008.
[92]. North, C.S., Hong, B.A. & Alpers, D.H. (2007). Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J. Gastroenterol., 13(14): 2020–2027. https://doi.org/10.3748/wjg.v13.i14.2020.
[93]. Owens, D.M., Nelson, D.K. & Talley, N.J. (1995). The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med., 122(2): 107–112. https://doi.org/10.7326/0003-4819-122-2-199501150-00005.
[94]. Jailwala, J., Imperiale, T.F. & Kroenke, K. (2000). Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med., 133(2): 136–147. https://doi.org/10.7326/0003-4819-133-2-200007180-00013.
[95]. Pae, C.-U., Lee, S.-J., Han, C., Patkar, A.A. & Masand, P.S. (2013). Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert Opin. Investig. Drugs, 22(5): 565–572. https://doi.org/10.1517/13543784.2013.782392.
[96]. Spiller, R. & Lam, C. (2012). An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J. Neurogastroenterol. Motil., 18(3): 258–268. https://doi.org/10.5056/jnm.2012.18.3.258.
[97]. Joo, J.S., Ehrenpreis, E.D., Gonzalez, L., Kaye, M., Breno, S., Wexner, S.D., Zaitman, D. & Secrest, K. (1998). Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J. Clin. Gastroenterol., 26(4): 283–286. https://doi.org/10.1097/00004836-199806000-00014.
[98]. Ruepert, L., Quartero, A.O., de Wit, N.J., van der Heijden, G.J., Rubin, G. & Muris, J.W.M. (2011). Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev., Issue 8. Art. No.: CD003460. https://doi.org/10.1002/14651858.CD003460.pub3.
[99]. Hou, X., Chen, S., Zhang, Y., Sha, W., Yu, X., Elsawah, H., Afifi, A.F., El-Khayat, H.R., Nouh, A., Hassan, M.F., Fatah, A.A., Joerg, I.R., Núñez, J.M.S., Rueda, R.O., Jurkowska, G., Walczak, M., Malecka-Panas, E., Linke, K., Hartleb, M. & Solingen, G.J.-v. (2014). Quality of Life in Patients with Irritable Bowel Syndrome (IBS), Assessed Using the IBS–Quality of Life (IBS-QOL) Measure After 4 and 8 Weeks of Treatment with Mebeverine Hydrochloride or Pinaverium Bromide: Results of an International Prospective Observational Cohort Study in Poland, Egypt, Mexico and China. Clin. Drug Invest., 34(11): 783–793. https://doi.org/10.1007/s40261-014-0233-y.
[100]. Simrén, M., Barbara, G., Flint, H.J., Spiegel, B.M.R., Spiller, R.C., Vanner, S., Verdu, E.F., Whorwell, P.J. & Zoetendal, E.G. (2013). Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut, 62(1): 159–176. https://doi.org/10.1136/gutjnl-2012-302167.
[101]. Clouse, R.E. (2003). Antidepressants for irritable bowel syndrome. Gut, 52(4): 598–599. https://doi.org/10.1136/gut.52.4.598.
[102]. Wald, A. (2002). Psychotropic agents in irritable bowel syndrome. J. Clin. Gastroenterol., 35(1 Suppl): S53–S57. https://doi.org/10.1097/00004836-200207001-00010.
[103]. Tack, J., Broekaert, D., Fischler, B., Van Oudenhove, L., Gevers, A.M. & Janssens, J. (2006). A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut, 55(8): 1095–1103. https://doi.org/10.1136/gut.2005.077503.
[104]. Vahedi, H., Merat, S., Rashidioon, A., Ghoddoosi, A. & Malekzadeh, R. (2005). The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment. Pharmacol. Ther., 22(5): 381–385. https://doi.org/10.1111/j.1365-2036.2005.02566.x.
[105]. Mustafa, M., Menon, J., Muniandy, R.K., Sien, M.M., Mustafa, S. & Fariz, A. (2015). Irritable Bowel Syndrome: Pathophysiology, Management and Treatment. IOSR Journal of Dental and Medical Sciences, 14(6): 70-76.
[106]. Aroniadis, O.C. & Brandt, L.J. (2013). Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol., 29(1): 79–84. https://doi.org/10.1097/MOG.0b013e32835a4b3e
[107]. Smits, L.P., Bouter, K.E., de Vos, W.M., Borody, T.J. & Nieuwdorp, M. (2013). Therapeutic potential of fecal microbiota transplantation. Gastroenterology, 145(5): 946–953. https://doi.org/10.1053/j.gastro.2013.08.058.
[108]. Klotz, U. (2012). The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid). Arzneimittelforschung, 62(2): 53–58. https://doi.org/10.1055/s-0031-1299685.
[109]. Pimentel, M., Chow, E.J. & Lin, H.C. (2000). Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol., 95(12): 3503–3506. https://doi.org/10.1016/S0002-9270(00)02161-4.
[110]. Pimentel, M., Chow, E.J. & Lin, H.C. (2003). Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol., 98(2): 412–419. https://doi.org/10.1111/j.1572-0241.2003.07234.x.
[111]. Parisi, G., Leandro, G., Bottona, E., Carrara, M., Cardin, F., Faedo, A., Goldin, D., Pantalena, M., Tafner, G., Verdianelli, G., Zilli, M. & AISGE Group (2003). Small intestinal bacterial overgrowth and irritable bowel syndrome. Am. J. Gastroenterol., 98(11): 2572–2574. https://doi.org/10.1111/j.1572-0241.2003.08686.x
[112]. O'Leary, C. & Quigley, E.M. (2003). Small bowel bacterial overgrowth, celiac disease, and IBS: what are the real associations? Am. J. Gastroenterol., 98(4): 720–722. https://doi.org/10.1111/j.1572-0241.2003.07395.x
[113]. Hasler, W.L. (2003). Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air? Gastroenterology, 125(6): 1898–1900. https://doi.org/10.1053/j.gastro.2003.08.038.
[114]. Posserud, I., Stotzer, P.O., Björnsson, E.S., Abrahamsson, H. & Simrén, M. (2007). Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut, 56(6): 802–808. https://doi.org/10.1136/gut.2006.108712.
[115]. Hammerle, C.W. & Surawicz, C.M. (2008). Updates on treatment of irritable bowel syndrome. World J. Gastroenterol., 14(17): 2639–2649. https://doi.org/10.3748/wjg.14.2639.
[116]. Pimentel, M., Park, S., Mirocha, J., Kane, S.V. & Kong, Y. (2006). The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med., 145(8): 557–563. https://doi.org/10.7326/0003-4819-145-8-200610170-00004.
[117]. Wouters, M.M., Vicario, M. & Santos, J. (2016). The role of mast cells in functional GI disorders. Gut, 65(1): 155–168. https://doi.org/10.1136/gutjnl-2015-309151.
[118]. Markowiak, P. & Śliżewska, K. (2017). Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients, 9(9): 1021. https://doi.org/10.3390/nu9091021.
[119]. Food and Agriculture Organization (FAO) Guidelines for the Evaluation of Probiotics in Food. FAO; London, ON, Canada: Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. 30 April–1 May 2002.
[120]. Brenner, D.M., Moeller, M.J., Chey, W.D. & Schoenfeld, P.S. (2009). The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol., 104(4): 1033–1049. https://doi.org/10.1038/ajg.2009.25.
[121]. Hussain, Z. & Quigley, E.M. (2006). Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment. Pharmacol. Ther., 23(4): 465–471. https://doi.org/10.1111/j.1365-2036.2006.02776.x
[122]. Laird, K.T., Tanner-Smith, E.E., Russell, A.C., Hollon, S.D. & Walker, L.S. (2017). Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. Clin. Psychol. Rev., 51: 142–152. https://doi.org/10.1016/j.cpr.2016.11.001.
[123]. Kinsinger S.W. (2017). Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol. Res. Behav. Manag., 10: 231–237. https://doi.org/10.2147/PRBM.S120817.
[124]. Hookway, C., Buckner, S., Crosland, P. & Longson, D. (2015). Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ, 350: h701. https://doi.org/10.1136/bmj.h701.
[125]. Laird, K.T., Tanner-Smith, E.E., Russell, A.C., Hollon, S.D. & Walker, L.S. (2016). Short-term and Long-term Efficacy of Psychological Therapies for Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol., 14(7): 937–947.e4. https://doi.org/10.1016/j.cgh.2015.11.020.
[126]. Lea, R., Houghton, L.A., Calvert, E.L., Larder, S., Gonsalkorale, W.M., Whelan, V., Randles, J., Cooper, P., Cruickshanks, P., Miller, V. & Whorwell, P.J. (2003). Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther., 17(5): 635–642. https://doi.org/10.1046/j.1365-2036.2003.01486.x.
[127]. Miller, V., Carruthers, H.R., Morris, J., Hasan, S. S., Archbold, S. & Whorwell, P.J. (2015). Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment. Pharmacol. Ther., 41(9): 844–855. https://doi.org/10.1111/apt.13145.
[128]. Farmer, A.D., Wood, E. & Ruffle, J.K. (2020). An approach to the care of patients with irritable bowel syndrome. CMAJ: Canadian Medical Association Journal, 192(11): E275–E282. https://doi.org/10.1503/cmaj.190716.
[129]. Johannesson, E., Simrén, M., Strid, H., Bajor, A. & Sadik, R. (2011). Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am. J. Gastroenterol., 106(5): 915–922. https://doi.org/10.1038/ajg.2010.480.
[130]. Dainese, R., Serra, J., Azpiroz, F. & Malagelada, J.R. (2004). Effects of physical activity on intestinal gas transit and evacuation in healthy subjects. Am. J. Med., 116(8): 536–539. https://doi.org/10.1016/j.amjmed.2003.12.018.
[131]. Asare, F., Störsrud, S. & Simrén, M. (2012). Meditation over medication for irritable bowel syndrome? On exercise and alternative treatments for irritable bowel syndrome. Curr. Gastroenterol. Rep., 14(4): 283–289. https://doi.org/10.1007/s11894-012-0268-2.
[132]. Daley, A.J., Grimmett, C., Roberts, L., Wilson, S., Fatek, M., Roalfe, A. & Singh, S. (2008). The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int. J. Sports Med., 29(9): 778–782. https://doi.org/10.1055/s-2008-1038600.
[133]. Wang, Y.T., Lim, H.Y., Tai, D., Krishnamoorthy, T.L., Tan, T., Barbier, S. & Thumboo, J. (2012). The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol., 12: 104. https://doi.org/10.1186/1471-230X-12-104.
[134]. Omagari, K., Murayama, T., Tanaka, Y., Yoshikawa, C., Inoue, S., Ichimura, M., Hatanaka, M., Saimei, M., Muto, K., Tobina, T., Masaki, M. & Kato, S. (2013). Mental, physical, dietary, and nutritional effects on irritable bowel syndrome in young Japanese women. Intern. Med., 52(12): 1295–1301. https://doi.org/10.2169/internalmedicine.52.0248.
[135]. Kuttner, L., Chambers, C.T., Hardial, J., Israel, D.M., Jacobson, K. & Evans, K. (2006). A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res. Manag., 11(4): 217–223. https://doi.org/10.1155/2006/731628.
[136]. van Tilburg, M.A., Palsson, O.S., Levy, R.L., Feld, A.D., Turner, M.J., Drossman, D.A. & Whitehead, W.E. (2008). Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement. Altern. Med., 8: 46. https://doi.org/10.1186/1472-6882-8-46.
[137]. Schumann, D., Anheyer, D., Lauche, R., Dobos, G., Langhorst, J. & Cramer, H. (2016). Effect of Yoga in the Therapy of Irritable Bowel Syndrome: A Systematic Review. Clin. Gastroenterol. Hepatol., 14(12): 1720–1731. https://doi.org/10.1016/j.cgh.2016.04.026.
[138]. Rej, A., Aziz, I., Tornblom, H., Sanders, D.S. & Simrén, M. (2019). The role of diet in irritable bowel syndrome: implications for dietary advice. J. Intern. Med., 286(5): 490–502. https://doi.org/10.1111/joim.12966.
[139]. Lenhart, A., Ferch, C., Shaw, M. & Chey, W.D. (2018). Use of Dietary Management in Irritable Bowel Syndrome: Results of a Survey of Over 1500 United States Gastroenterologists. J. Neurogastroenterol. Motil., 24(3): 437–451. https://doi.org/10.5056/jnm17116.
[140]. El-Salhy, M. & Gundersen, D. (2015). Diet in irritable bowel syndrome. Nutr. J., 14: 36. https://doi.org/10.1186/s12937-015-0022-3.
Published
2020-09-05
How to Cite
HAMARASHID, B., DALKILIÇ, S., DALKILIÇ, L., SALEH, K., & KIRBAĞ, S. (2020). Irritable Bowel Syndrome (IBS): A Review. Journal of Advanced Laboratory Research in Biology, 11(3), 36-52. Retrieved from https://e-journal.sospublication.co.in/index.php/jalrb/article/view/337
Section
Articles
Abstract viewed = 50 times, PDF downloaded = 16 times